HideChilds = False
SystemName =
 

In the United States, ALPROLIX® is indicated for: on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Delivering innovative therapies

Haemophilia B

ALPROLIX® is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia B (congenital factor IX deficiency) for:

  • Control and prevention of bleeding episodes
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
  • Perioperative management (surgical prophylaxis)

ALPROLIX is manufactured using a human cell line in an environment free of animal and human additives.

ALPROLIX is approved for use for the treatment of Haemophilia B in Australia and New Zealand. It is also approved in the United States, Japan, Canada, and other countries.